VEGFA and Retinal atrophy: Additionally, clinical studies, including randomized controlled trials and systematic reviews, demonstrate a correlation between the frequency of anti-VEGF injections and incidence of RPE atrophy [13, 31, 32]. Furthermore, a study by Cho et al. compared the efficacy of ranibizumab and aflibercept in Type 3 MNV and reports that the aflibercept group, which exhibited a stronger VEGF suppression effect than the ranibizumab group, had a higher incidence of retinal atrophy [33].